Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

Blood Reviews

Volumn 23, Issue 2, 2009, Pages 87-93

  Palumbo, Antonio ^a   Dimopoulos, Meletios ^b   Miguel, Jesus San ^c   Harousseau, Jean Luc ^d   Attal, Michel ^e   Hussein, Mohamad ^f   Knop, Stefan ^g   Ludwig, Heinz ^h   von Lilienfeld Toal, Marie ⁱ   Sonneveld, Pieter ^j  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HÔTEL DIEU   (France)

^e CHU PURPAN   (France)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Cytopenia; Dexamethasone; Lenalidomide; Multiple myeloma; Venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; BORTEZOMIB; COLONY STIMULATING FACTOR; DEXAMETHASONE; DIGOXIN; LENALIDOMIDE; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; WARFARIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CYTOGENETICS; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INSOMNIA; KIDNEY FAILURE; LIVER FAILURE; LUNG EDEMA; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PARESTHESIA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; VEIN THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 61349118005     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.07.003     Document Type: Article

References (53)

1. Piazza F.A., Gurrieri C., Trentin L., and Semenzato G. Towards a new age in the treatment of multiple myeloma. Ann Hematol 86 (2007) 159-172
2. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 (2003) 21-33
3. TM. Multiple Myeloma. V.1.2008. [accessed 4.10.2007].
4. Smith A., Wisloff F., and Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132 (2006) 410-451
5. Kumar S., and Rajkumar S.V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42 (2006) 1612-1622
6. Kastritis E., and Dimopoulos M.A. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 8 (2007) 497-509
7. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 (2004) 314-322
8. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
9. Richardson P, Jagannath S, Hussein M, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood (ASH Annual Meeting Abstracts) 2005; 106: [Abstract 1565].
10. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
11. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 6 (2006) 1165-1173
12. Weber D.M., Chen C., Niesvizky R., et al. For the Multiple Myeloma-009 Study Investigators. Oral lenalidomide plus dexamethasone for relapsed/refractory multiple myeloma. N Eng J Med 357 (2007) 2133-2142
13. Dimopoulos M., Spencer A., Attal M., et al. For the Multiple Myeloma-010 Study Investigators. Lenalidomide plus dexamethasone versus dexamethasone alone for relapsed or refractory multiple myeloma. N Eng J Med 357 (2007) 2123-2132
14. ®) lenalidomide. Br J Cancer 93 (2005) 613-619
15. Anagnostopoulos A., Dimopoulos M.A., Spencer A., et al. A randomized phase 3 trial of oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Final analysis of MM010 study. Haematologica 92 s2 (2007) [Abstract PO-661]
16. ® prescribing information. [accessed 4.10.2007].
17. ®) plus dexamethasone in over 1400 subjects with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3556].
18. Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
19. Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3547].
20. Bennett C.L., Angelotta C., Yarnold P.R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296 (2006) 2558-2560
21. Knight R., DeLap R.J., and Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354 (2006) 2079-2080
22. Rajkumar S.V., and Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354 (2006) 2079-2080
23. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
24. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (ASCO Annual Meeting Abstracts) 2007; 25 (June 20 Suppl.): [Abstract LBA8025].
25. Sviggum H.P., Davis M.D., Rajkumar S.V., and Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142 (2006) 1298-1302
26. Stadtmauer E., Weber D., Dimopoulos M., et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 108 (2006) [Abstract 3552]
27. Chanan-Khan AA, Yu Z, Weber D, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3554].
28. Wang M., Knight R., Dimopoulos M., et al. Effect of Len/Dex in MM despite Thal resistance. Haematologica 92 s2 (2007) [Abstract PO-662]
29. Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3557].
30. Kristinsson S.Y., Landgren O., Dickman P.W., Derolf A.R., and Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25 (2007) 1993-1999
31. Chanan-Khan AA, Weber D, Dimopoulos M, et al. Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2006; 108: [Abstract 3551].
32. Lonial S., Knight R., Dimopoulos M., et al. Effect of Len/Dex in MM in different age groups. Haematologica 92 s2 (2007) [Abstract PO-663]
33. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47 (2007) 1466-1475
34. US Food and Drug Administration. Information on Erythropoiesis Stimulating Agents (ESA). [accessed 8.1.2008].
35. Cunningham R.S. Therapeutic options for the treatment of cancer-associated thrombosis. Semin Oncol Nurs 21 4 Suppl 1 (2005) 21-40
36. Zangari M., Barlogie B., Thertulien R., et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 4 (2003) 32-35
37. Srkalovic G., Cameron M.G., Rybicki L., Deitcher S.R., Kattke-Marchant K., and Hussein M.A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101 (2004) 558-566
38. Khorana A.A., Francis C.W., Culakova E., and Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
39. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., and Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24 (2006) 484-490
40. Niesvizky R., Spencer A., Wang M., et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. J Clin Oncol (ASCO Annual Meeting Abstracts) 24 (2006) (June 20 Suppl.): [Abstract 7506]
41. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (2005) 1568-1574
42. Baz R., Walker E., Karam M.A., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17 (2006) 1766-1771
43. Zonder J.A., Durie B.G., McCoy J., et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood (ASH Annual Meeting Abstracts) 106 (2005) [Abstract 3455]
44. Hussein M.A. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95 (2006) 924-930
45. Fitzmaurice D.A., Blann A.D., and Lip G.Y. Bleeding risks of antithrombotic therapy. BMJ 325 (2002) 828-831
46. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
47. Lee A.Y., Levine M.N., Baker R.I., et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
48. Lim W., Dentali F., Eikelboom J.W., and Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
49. Oken M.M., Pomeroy C., Weisdorf D., and Bennett J.M. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100 6 (1996) 624-628
50. Thornburg A., Abonour R., Smith P., Knox K., and Twigg III H.L. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest 131 (2007) 1572-1574
51. Boccadoro M., Palumbo A., Bringhen S., et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87 (2002) 846-850
52. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21 (2007) 2035-2042
53. TM. Cancer-Related Fatigue. V.4.2007. [accessed 4.10.2007].